本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 证券代码：000615 证券简称：*ST美谷 公告编号：2025-110 奥园美谷科技股份有限公司 出资人组会议暨 2025 年第四次临时股东会决议公告 1、本次会议无否决提案的情形； 2、本次会议不涉及变更以往股东会已通过决议的情形。 一、会议的召开情况 1、会议召开时间： （1）现场会议时间：2025 年 12 月 15 日（星期一）下午 15:00 开始； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年12月15日的交易时间，即上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 12 月 15 日 上午 9:15 至下午 15:00 间的任意时间。 2、现场会议召开地点：湖北省襄阳市樊城区汉江街道办事处长虹路 17 号长 虹会务服务中心九楼。 3、会议召开及表决方式：现场投票与网络投票结合的方式召开 4、召集人：公司管理人 5、主持人：公司管理人代表和公司董事长 6、股权登 ...

关于奥园美谷科技股份有限公司出资人组会议暨 2025 年第四次临时股东会的法律意见书 君達律師事務所 aw Hirm 广东广信君达律师事务所 关于奥园美谷科技股份有限公司出资人组会议 暨 2025年第四次临时股东会的 法律意见书 (2025) 广信君达律见字第 117786-5 号 致:奥园美谷科技股份有限公司 广东广信君达律师事务所(以下简称"本所")接受奥园美谷科技股份有 限公司（以下简称"公司"）的委托,指派杨尹、吴震宇律师（以下简称"本 所律师"）出席公司于 2025年 12 月 15 目召开的出资人组会议暨 2025 年第四 次临时股东会（以下简称"本次会议"）,并获授权依据 《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国企业破产法》（以下简称 《破产法》）、《深圳证券交易所股票上市规则》（以下简称《股票上市规 则》）、《深圳证券交易所上市公司自律监管指引第 14号 -- 破产重整等事项》 〈以下简称《14 号指引》）等法律、行政法规和规范性文件〈以下统称"法律 法规"）及《奥园美谷科技股份有限公司章程》（以下简称《公司章程》）的 有关规定出具本法律意见书。 为出具本法律意见,本 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-108 奥园美谷科技股份有限公司 关于重大诉讼事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 一、诉讼案件的基本情况 中国银行股份有限公司襄阳分行（以下简称"中行襄阳分行""原告"）因 金融借款合同纠纷向湖北省襄阳市中级人民法院（以下简称"襄阳中院"）提起 诉讼，请求法院判令：原告中行襄阳分行与被告湖北金环绿色纤维有限公司（以 下简称"金环绿纤"）签订《固定资产借款合同》项下全部贷款本息立即到期， 判令被告金环绿纤偿还原告本金 225,395,211.17 元，利息及复利、罚息；判令 各担保方履行担保责任以及判令用于抵押的设备、房屋及土地使用权折价或者拍 卖、变卖后所得价款在原告请求的债务范围内优先受偿；财产保全费、案件受理 费、律师代理费用等由被告共同承担。经与中行襄阳分行协商，金环绿纤及各担 保方与中行襄阳分行签署《调解协议》，后由襄阳中院依此调解并出具（2023） 鄂 06 民初 11 号《民事调解书》。具体详见奥园美谷科技股份有限公司（以下简 称"公司"）分别 ...

关于公司持股 5%以上股东所持部分股份被司法拍卖的进展 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次司法拍卖的基本情况 奥园美谷科技股份有限公司（以下简称"公司"）通过"淘宝网"网络司法 拍卖平台（https://sf-item.taobao.com）查询，获悉目前公司持股 5%以上股 东京汉控股集团有限公司（以下简称"京汉控股"）所持公司的 45,373,219 股 股票将于 2025 年 8 月 30 日上午 10 时至 2025 年 8 月 31 日上午 10 时止（延时的 除外）在"淘宝网"网络司法拍卖平台被上海市浦东新区人民法院公开拍卖。具 体内容详见公司于 2025 年 7 月 18 日在巨潮资讯网（www.cninfo.com.cn，下同） 披露的《关于公司持股 5%以上股东所持部分股份将被司法拍卖的提示性公告》。 2025 年 8 月 29 日，公司通过"淘宝网"网络司法拍卖平台查询，其显示上 述司法拍卖已暂缓，具体内容详见公司于 2025 年 8 月 30 日在巨潮资讯网披露的 《关于公司持股 5%以上股东所持部分股份被司法 ...

奥园美谷科技股份有限公司 关于控股子公司债务逾期的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、控股子公司债务逾期情况概述 证券代码：000615 证券简称：*ST美谷 公告编号：2025-107 奥园美谷科技股份有限公司（以下简称"公司"）控股子公司湖北金环绿色 纤维有限公司（以下简称"金环绿纤"）、湖北金环新材料科技有限公司（以下 简称"金环新材料"）和广州奥美产业投资有限公司（以下简称"奥美产投"） 出现部分债务未能如期偿还的情形，公司及其控股子公司对前述逾期债务提供了 连带责任担保，具体详见 2024 年 11 月 28 日、2025 年 1 月 10 日、2 月 6 日、2 月 18 日、3 月 8 日、3 月 22 日、5 月 21 日、6 月 24 日、7 月 12 日、8 月 20 日 和 9 月 23 日刊登在巨潮资讯网（www.cninfo.com.cn，下同）的《关于控股子公 司债务逾期的公告》（公告编号：2024-116）、《关于控股子公司债务逾期的公 告》（公告编号：2025-002）、《关于控股子公司债务逾期的进展公 ...

Group 1 - The medical beauty sector experienced a decline of 1.38% on December 9, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 3909.52, down 0.37%, while the Shenzhen Component Index closed at 13277.36, down 0.39% [1] - A detailed table of individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector saw a net outflow of 16.9357 million yuan from main funds, and a net outflow of 2.5367 million yuan from speculative funds, while retail investors had a net inflow of 19.4724 million yuan [2] - A detailed table of capital flow for individual stocks in the medical beauty sector is included [2]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-105 奥园美谷科技股份有限公司 关于出资人组会议暨 2025 年第四次临时股东会补充通知的 公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日在 《证券时报》和巨潮资讯网（www.cninfo.com.cn，下同）刊登了《关于召开出 资人组会议暨 2025 年第四次临时股东会的通知》，定于 2025 年 12 月 15 日召开 出资人组会议暨 2025 年第四次临时股东会。 2025 年 12 月 1 日，公司召开了第十一届董事会第二十九次会议，审议通过 了《关于续聘 2025 年度审计机构的议案》，同意续聘中审众环会计师事务所（特 殊普通合伙）为公司 2025 年度审计机构，负责公司 2025 年度财务报告及内部控 制等审计工作，该议案尚需提交公司股东会审议。股东深圳奥园科星投资有限公 司（以下简称"奥园科星"）于 2025 年 12 月 2 日送达了其出具的《关于提议奥 园美谷出资人组会议暨 2025 年第 ...

Core Viewpoint - The restructuring of *ST Meigu (000615.SZ) is a focal point for the market, with the company seeking to emerge from its current difficulties through a comprehensive restructuring plan and the appointment of an auditing firm for oversight [1][3]. Restructuring Plan - The board of *ST Meigu has approved the reappointment of Zhongshun Zhonghuan Accounting Firm as the auditing agency for the fiscal year 2025, pending approval from a temporary shareholders' meeting [1]. - The restructuring plan includes the recruitment of investors, with three main investors identified: Hubei Jiuzhou Industrial Park Operation Management Co., Tianjin Xinmeitongcheng Equity Investment Partnership, and six financial investors [4][5]. - The restructuring plan proposes a capital increase of approximately 10.24 billion shares, raising the total share capital to 17.87 billion shares, with a conversion ratio of 13.4278 shares for every 10 shares held [5]. Financial Details - Approximately 8.6 billion shares from the capital increase will be allocated to introduce restructuring investors, with a total investment amount of 1.536 billion yuan, where Hubei Jiuzhou accounts for 706 million yuan, nearly 46% of the total [5]. - The restructuring investors will use part of the shares for debt settlement with related guarantee creditors, and they will not be allowed to seek further compensation from *ST Meigu for these shares [5]. Business Strategy - Post-restructuring, *ST Meigu plans to leverage the funds and resources from industrial investors to strengthen its existing beauty and health services while expanding into related businesses within the health industry [6]. - The company aims to acquire quality assets related to its main business through retained funds and share issuance after the restructuring [6]. Medical Aesthetics Focus - *ST Meigu's core asset remains its medical aesthetics business, which began in 2021 with a 697 million yuan acquisition of a 55% stake in Zhejiang Liantianmei [6][7]. - The company has formed strategic partnerships with various entities in the medical aesthetics sector, although its real estate business has faced challenges leading to financial losses [7]. - In 2023, *ST Meigu was placed under "delisting risk warning" due to its inability to repay debts, prompting a restructuring application [7]. Investor Background - Jiuzhou Tong, through its subsidiary Jiuzhou Chuantou, signed a restructuring investment agreement with *ST Meigu, potentially becoming the controlling shareholder if the restructuring is successful [8]. - Jiuzhou Tong has been investing in the medical aesthetics sector since 2016, with significant growth in its medical aesthetics business, achieving a sales revenue of 851 million yuan in 2024, a 120.47% increase year-on-year [9]. - The company reported a compound annual growth rate of 111.64% in sales revenue from 2022 to 2024, indicating a robust growth trajectory in the medical aesthetics market [9].

Core Viewpoint - The restructuring of *ST Meigu (000615.SZ) is a focal point for the market, with the company announcing the reappointment of Zhongshang Zhonghuan Accounting Firm as its auditor for the 2025 fiscal year, pending approval from a temporary shareholders' meeting [2] Restructuring Plan - *ST Meigu has revealed details of its restructuring plan, identifying Hubei Jiuzhou Industrial Park Operation Management Co., Ltd. and Tianjin Xinmeitongcheng Equity Investment Partnership as key investors, along with six financial investors [4] - The restructuring plan involves a capital increase of approximately 1.024 billion shares, raising the total share capital to 1.787 billion shares, based on a ratio of 13.4278 shares for every 10 shares held [4] - The newly issued shares will be used primarily for three purposes: resolving related guarantee issues, compensating creditors with shares, and attracting restructuring investors [4] Financial Investment - Approximately 860 million shares will be allocated to attract restructuring investors, with a total investment amount of 1.536 billion yuan, where Hubei Jiuzhou will contribute 706 million yuan, accounting for nearly 46% of the total [4][5] Business Strategy Post-Reconstruction - After the restructuring, *ST Meigu plans to leverage the funds and resources from industrial investors to strengthen its existing beauty and health services while expanding into related businesses and enhancing its health industry chain [6] - The company aims to acquire quality assets related to its main business through retained funds and share issuance post-restructuring [7] Medical Aesthetics Focus - *ST Meigu's core asset remains in the medical aesthetics sector, having entered this market in 2021 with a significant acquisition of a 55% stake in Zhejiang Liantianmei for 697 million yuan [7] - The company has established strategic partnerships with various entities in the medical aesthetics field, although it faced challenges due to the downturn in the real estate sector, leading to continuous losses and financial distress [7][8] Potential Control Change - If the restructuring is successful, Jiuzhou Tong may become the controlling shareholder of *ST Meigu, as it has been actively investing in the medical aesthetics sector since 2016 [8] - Jiuzhou Tong's medical aesthetics business has shown significant growth, with sales revenue reaching 851 million yuan in 2024, a 120.47% increase year-on-year, and 904 million yuan in the first three quarters of the current year, up 45.84% [8][9]

Core Insights - The medical beauty sector experienced a decline of 0.65% on December 2, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Sector Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - Jinbo Biological: Closed at 223.43, up 2.42% with a trading volume of 11,300 hands and a transaction amount of 253 million [1] - *ST Meigu: Closed at 4.17, up 0.97% with a trading volume of 91,900 hands and a transaction amount of 37.83 million [1] - Aimeike: Closed at 145.06, down 0.64% with a trading volume of 16,000 hands and a transaction amount of 233 million [1] - Huaxi Biological: Closed at 46.57, down 0.89% with a trading volume of 20,600 hands and a transaction amount of 96.12 million [1] Capital Flow - The medical beauty sector saw a net outflow of 1.145 million from main funds, while retail investors had a net inflow of 1.233 million [1] - Detailed capital flow for key stocks is as follows: - Jinbo Biological: Main funds net inflow of 25.696 million, retail net inflow of 636,300 [2] - Huaxi Biological: Main funds net inflow of 4.2399 million, retail net inflow of 939,100 [2] - *ST Meigu: Main funds net inflow of 857,200, retail net inflow of 2.3685 million [2] - Aimeike: Main funds net outflow of 6.2421 million, retail net inflow of 9.0204 million [2]